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Background and objective: Indicators to measure the quality of healthcare are increasingly used by
healthcare professionals and policy makers. In the context of increasing antimicrobial resistance, this study
aimed to develop valid drug-specific quality indicators for outpatient antibiotic use in Europe, derived from
European Surveillance of Antimicrobial Consumption (ESAC) data.
Methods: 27 experts (15 countries), in a European Science Foundation workshop, built on the expertise
within the European Drug Utilisation Research Group, the General Practice Respiratory Infections Network,
the ESCMID Study Group on Primary Care Topics, the Belgian Antibiotic Policy Coordination Committee, the
World Health Organization, ESAC, and other experts. A set of proposed indicators was developed using
1997–2003 ESAC data. Participants scored the relevance of each indicator to reducing antimicrobial
resistance, patient health benefit, cost effectiveness and public health policy makers (scale: 1 (completely
disagree) to 9 (completely agree)). The scores were processed according to the UCLA-RAND appropriateness
method. Indicators were judged relevant if the median score was not in the 1–6 interval and if there was
consensus (number of scores within the 1–3 interval was fewer than one third of the panel). From the relevant
indicators providing overlapping information, the one with the highest scores was selected for the final set of
quality indicators—values were updated with 2004 ESAC data.
Results: 22 participants (12 countries) completed scoring of a set of 22 proposed indicators. Nine were rated
as relevant antibiotic prescribing indicators on all four dimensions; five were rated as relevant if only
relevance to reducing antimicrobial resistance and public health policy makers was taken into account. A final
set of 12 indicators was selected.
Conclusion: 12 of the proposed ESAC-based quality indicators for outpatient antibiotic use in Europe have
face validity and are potentially applicable. These indicators could be used to better describe antibiotic use in
ambulatory care and assess the quality of national antibiotic prescribing patterns in Europe.
Q
uality assessment and improvement in healthcare is a
major issue in many countries.1 2 Information on quality
of healthcare is being demanded by policy makers,
healthcare professionals and the general public.3 With most
doctor–patient encounters in general practice resulting in a
prescription for drug treatment, the quality of prescribing in
general practice is an important issue.4 Prescribing also has a
major influence on well-being and accounts for a substantial
part of healthcare expenditure.5 The above statements hold true
for antibiotics as well. In addition, antibiotic consumption is
increasingly recognised as the main driver of resistance.6–8
Antibiotic resistance is a major European and global public
health problem, and international efforts are needed to
counteract its emergence.
There is a wealth of information on the prevalence of
resistance in human pathogens, and these data show sub-
stantial geographical differences in the proportion of resistance
to various classes of antibiotics in Europe.9 10 Whereas the rates
of resistance remain low in northern European countries, they
are reaching alarming levels in southern and central European
countries. Studies have shown that differential selection
pressure of antibiotic agents may be responsible for some of
these observed differences.6 7 Consequently antimicrobial con-
sumption was to be monitored to accompany analogous
surveillance programmes on resistance.11
The European Surveillance of Antimicrobial Consumption
(ESAC; www.ua.ac.be/ESAC) project, granted by DG SANCO of
the European Commission, was launched in 2001. ESAC is an
international network of surveillance systems, aiming to collect
comparable and reliable data on antibiotic use in Europe. The
methods and initial results have been published.7 12 The largest
volumes of antibiotic prescriptions for systemic use are
prescribed in primary care, with respiratory tract infections
being the most common indication. More detailed analysis of
antibiotic use in outpatients again showed considerable
differences in overall antibiotic use, the use of the different
kinds of antibiotics, and seasonal variation of antibiotic use,
suggesting inappropriate antibiotic use in Europe,13–17 as these
striking variations cannot be explained by differences in
incidence of disease alone or by differences in aetiology or
resistance rates between countries.
If we want to improve the use of antibiotics, we have to be
able to measure the quality of antibiotic use in Europe.
Therefore, our aim was to develop a set of valid drug-specific
quality indicators for outpatient antibiotic use in Europe, which
can be derived from ESAC data, taking into account the
recommendations of DURQUIM (Drug Utilisation Research
Quality Indicator Meeting).18
Abbreviations: ATC, Anatomic Therapeutic Chemical (classification);
DDD, defined daily dose; DID, DDD per 1000 inhabitants per day; ESAC,
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METHODS
Developing a set of quality indicators
Quality indicators are defined as explicitly defined measurable
items of antibiotic use giving a possible indication of the level of
quality,19 20 focusing on different aspects of quality (effective-
ness, safety, appropriateness and costs,21 compliance, and
persistence) and relevant to clinical practice.22 To produce a
list of proposed quality indicators for outpatient antibiotic use
in Europe based on ESAC data, a workshop was convened,
funded by the European Science Foundation (ESF) (see fig 1
for a flowchart of the stages of development).18 This provided
the unique opportunity to build on the interdisciplinary
expertise within EuroDURG (European Drug Utilisation
Research Group; www.eurodurg.com), GRIN (General
Practice Respiratory Infections Network), ESPRIT (ESCMID
Study Group on Primary Care Topics; www.escmid.org/esprit),
BAPCOC (Belgian Antibiotic Policy Coordination Committee;
www.bapcoc.be), WHO (World Health Organization;
www.who.int), ESAC and other experts in this field. To prepare
the workshop and to propose a draft list of indicators a
scientific advisory board was set up with members of
EuroDURG, GRIN/ESPRIT and of the ESAC Management
Team. These clinicians and scientists, not policy makers, with
expertise in general practice, microbiology, infectious diseases,
pharmacoepidemiology, pharmacy and/or drug utilisation
decided that the workshop should:
N allow discussion on the development of quality indicators
from the perspective of professionals and policy makers;
N produce a proposed set of quality indicators for outpatient
antibiotic;
N produce a roadmap describing the next steps with these
indicators.
The workshop included smaller work groups and plenary
sessions. More details on the method of indicators development
have been described elsewhere.23 After 2 days of relevant
background presentations, constructive feedback and fruitful
discussions, the participants produced an agreed set of
proposed indicators related to the quality of outpatient
antibiotic use (table 1 and S1 in online supplement at http://
qshc.bmj.com/supplemental).
Assessing a set of quality indicators
To assess the relevance of the proposed quality indicators two
consecutive cycles of scoring were conducted: one during the
workshop and one after the workshop by email to finalise the
process. All 27 participants (7 women; 15 countries) were asked
to score the relevance of each of the proposed indicators to:
N reducing antimicrobial resistance;
N patient health benefit;
N cost effectiveness;
N public health policy makers.
The scale for scoring ranged from 1 ( = completely disagree)
through 5 ( = uncertain) to 9 ( = completely agree). The scores
were processed according to the UCLA-RAND appropriateness
method.24 25 Proposed indicators were judged relevant if the
median score was not within the 1–6 interval and if there was
consensus—that is, if the number of scores within the 1–3
interval was fewer than one third of the panel. Along with the
scores we asked for comments on the indicators. These were
taken into account in earlier versions of this manuscript, which
were reviewed and later approved by all participants.
Defining a final set of quality indicators
To define the final set only relevant indicators were selected.
From relevant indicators providing overlapping information
only the one with the highest scores for relevance was selected
for the final set of quality indicators.
Figure 1 Stages in the development of
quality indicators for outpatient antibiotic use
in Europe derived from ESAC data.
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Applying a final set of quality indicators
The set of proposed quality indicators was developed using
1997–2003 ESAC data on outpatient antibiotic use in Europe.13–17
These ESAC data are use data of systemic antibiotics for
ambulatory care, aggregated at the level of the active substance
in accordance with the Anatomic Therapeutic Chemical (ATC)
classification and defined daily dose (DDD) measurement unit
(WHO, version 2005)—for example, amoxicillin, ATC code:
J01CA04, DDD: 1 g.26 The DDD is the assumed average
maintenance dose per day for a drug used for its main indication
in adults.26 The antibiotic use is expressed in DDD per 1000
inhabitants per day (DID). The numbers of inhabitants in the
European countries were the mid-year population of the countries
involved.27 A complete description of the data providers, details of
the methodology used and the associated problems, and indepth
discussions of the validity of the collected data have been
published previously.12
The values of the final set of relevant indicators were
calculated using the most recent—that is, 2004 ESAC data. For
each of the indicators we grouped the indicator values into four
quartiles, and used this grouping in maps depicting the
indicator values for all countries participating in ESAC.
RESULTS
A set of 22 proposed indicators was developed during the ESF
workshop. The first of these indicators was the yearly use of
antibiotics expressed in DID. The next 12 reflected the use of
the six main subclasses of antibiotics expressed in DID and as
percentage of the total antibiotic use. Four additional indicators
reflected the use of four smaller therapeutic groups, again
expressed as percentage of the total antibiotic use. There was
one ratio (use of broad over narrow spectrum antibiotics), three
indicators for seasonal variation of use (one for the total
antibiotic use, and a similar and a more complex one for
quinolone use). Finally, there was an indicator of longitudinal
trends (table 1 and table S1 (see http://qshc.bmj.com/supple-
mental)).
We received scores from 22 participants (6 women; 12
countries). Nine indicators were rated as relevant antibiotic
prescribing indicators on all four dimensions, and five addi-
tional indicators were rated as relevant if only relevance to
reducing antimicrobial resistance and to public health policy
makers was taken into account (table 1).
The information provided by ‘‘Consumption of quinolones
(J01M) in percentage’’ and ‘‘Seasonal variation of quinolone
consumption (J01M) multiplied by their use in DID’’ over-
lapped with the information provided by ‘‘Consumption of
fluoroquinolones (J01MA) in percentage’’ and ‘‘Seasonal
variation of quinolone consumption (J01M)’’, respectively,
but the latter indicators scored higher for relevance.
Table 2 shows the values for the final set of 12 quality
indicators for 28 European countries in 2004. The indicator
values for the period 1997–2003 are available online (table S2–
8; see http://qshc.bmj.com/supplemental). For ‘‘Consumption
of antibacterials for systemic use (J01) expressed in DID’’,
figure 2 depicts the grouping of 28 European countries based on
the distribution of the respective indicator values for 2004 in
four quartiles. Maps presenting the 2004 indicator values for
the other relevant indicators are available online (figs S1–11;
see http://qshc.bmj.com/supplemental).
DISCUSSION
Taking into account the scores from a relevant group of
experts—professionals rather than policy makers—and the
2004 indicator values of 28 individual European countries, from
a set of proposed ESAC based quality indicators for outpatient
antibiotic use in Europe a final set of 12 indicators seems to be
relevant—that is, has face validity and is potentially applicable.
The indicators scored higher on the dimensions ‘‘resistance’’
and ‘‘public health policy’’ than on ‘‘patient health benefit’’ and
‘‘cost effectiveness’’.
The most useful indicator probably is ‘‘Consumption of
antibacterials for systemic use (J01) expressed in DID’’, since
overall this is likely to best indicate the size of the pressure
driving antibiotic resistance, which in turn is highly relevant for
Table 2 Quality indicators for outpatient antibiotic use in Europe: indicator values for 28 European countries in 2004
J01_DID J01C_DID J01D_DID J01F_DID J01M_DID J01CE_% J01CR_% J01DD+DE_% J01MA_% J01_B/N J01_SV J01M_SV
Austria 12.61 5.12 1.56 3.05 1.50 8.4 24.3 11.8 11.9 5.17 27.6 16.8
Belgium 22.90 10.60 3.16 2.35 2.48 0.6 28.3 0.0 10.8 27.73 36.1 18.4
Bulgaria 16.39 7.71 1.68 1.02 1.60 5.2 8.5 0.9 9.8 1.43 29.7 16.1
Croatia 23.02 11.82 3.42 2.25 1.46 7.3 21.7 1.7 6.3 2.37
Czech Republic 15.58 6.81 0.95 2.67 1.27 12.3 16.7 0.0 8.1 2.86 25.1 2.9
Denmark 14.15 8.87 0.02 2.25 0.28 37.0 0.4 0.0 2.0 0.22 17.3 7.9
Estonia* 11.34 4.52 0.61 1.08 0.64 2.1 5.5 0.0 5.6 1.59 42.2 9.2
Finland 17.27 5.11 2.14 1.89 0.83 9.1 4.8 0.0 4.8 0.75 19.6 5.8
France 27.09 12.83 3.07 4.31 2.08 0.6 19.2 5.7 7.2 20.47
Germany 11.09 3.43 1.07 1.81 0.98 9.0 1.5 2.8 8.8 1.96 37.8 26.6
Greece` 33.38 10.47 7.23 9.85 1.89 0.8 15.6 0.7 5.7 24.34 20.3 232.0
Hungary 18.59 8.56 2.25 3.16 1.67 6.0 24.9 2.4 9.0 7.38 37.8 5.4
Iceland` 21.44 11.07 0.44 1.67 0.65 13.6 12.8 0.3 3.0 1.01 17.8 8.6
Ireland 20.69 9.98 1.95 2.93 0.77 4.1 23.0 0.7 3.6 4.59 21.3 7.8
Israel 19.69 11.66 3.50 1.51 1.09 8.2 17.2 0.1 5.5 2.81 16.1 25.8
Italy* 25.69 12.35 3.37 5.01 3.02 0.0 22.5 7.7 10.6 50.87 37.0 22.5
Latvia 11.80 5.38 0.33 0.92 0.90 1.6 10.1 0.1 7.1 2.98
Luxembourg 24.17 10.49 4.59 2.68 2.41 0.7 26.2 0.0 10.0 14.97 15.3 0.4
The Netherlands 9.75 3.76 0.05 1.38 0.84 4.3 14.1 0.1 8.4 5.12
Norway 15.88 6.63 0.28 1.82 0.44 24.8 0.0 0.0 2.8 0.15
Poland 21.14 9.86 2.04 2.37 1.10 2.2 10.2 0.1 4.5 6.04 38.6 14.8
Portugal 23.84 11.21 3.23 3.67 3.05 0.4 30.7 2.1 12.8 13.48 31.8 12.8
Russia 9.15 2.22 0.19 0.96 1.30 1.8 3.2 0.4 13.4 2.18
Slovakia 22.43 12.50 2.15 3.30 1.33 20.3 15.2 0.4 5.9 1.67 41.3 3.0
Slovenia 16.82 9.91 0.72 3.21 1.12 14.9 24.1 0.4 6.5 3.03 29.4 8.8
Spain 18.70 10.85 1.82 2.45 2.33 0.5 34.7 2.6 12.0 40.00 30.3 14.9
Sweden 14.67 6.61 0.40 0.83 0.99 26.8 1.3 0.1 6.8 0.15 9.6 5.4
UK 15.21 7.02 0.78 2.27 0.50 4.2 6.1 0.0 3.2 0.56 15.2 5.7
*2003 data; 2002 data; ` total antibiotic use data.
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public health.7 Other indicators should probably not be assessed
individually—for example, a low ‘‘Consumption of penicillins
(J01C) expressed in DID’’ apparently reflects good practice, but
along with a high consumption of cephalosporins (J01D),
macrolides, lincosamides and streptogramins (J01F) and
quinolones (J01M) it suggests poor practice. All these other
substances should be second-line drugs given the limited
evidence of additional clinical benefit over penicillins for the
most common indication, respiratory infections, and their
increased costs. Similarly high or increasing trends in the
percentage use of broad spectrum penicillins, cephalosporins and
of fluoroquinolones would usually indicate poor practice, but not
so much if overall consumption is coming down. Marked seasonal
variation in antibiotic and quinolone use is likely to reflect poorer
practice, since it represents higher use of antibiotics for respiratory
infections, which has a poor evidence base.
The value of this set is associated with the self-imposed
limitation to handle only those indicators that can be generated
by the ESAC database. After all, one could argue that mere use
data cannot indicate quality without being related to clinical
information. This was, for instance, done in a Dutch study in
which clinical information from individual patients was linked
to antibiotic use and guidelines were used as a quality
benchmark.28 This was even done on a national scale in the
Netherlands,29 but in many European countries this is not
feasible at present. Being able to use easily available national
data that are valid and can be extracted from most European
countries—34 European countries participate in ESAC in
2006—to produce the indicator values, can thus be considered
as a strong side as well.
Nevertheless, more work will need to be done to improve the
assessment of the quality of outpatient antibiotic use. Although
we consider our data to be objective and available, and our
indicators to have face validity and to be remediable, other
attributes of the data, for example, the need for adjusting for
contextual factors, and of the indicators, for example,
concurrent and construct validity, and acceptability by those
being assessed, need to be dealt with in future research
activities. Conversely, we could argue that for some of the
indicators content validity has been proven, since there is
evidence for a (causal) link between the use of particular
antibiotics with antimicrobial resistance for these antibiotics
both on an ecological level7 and an individual level.8
One could consider limiting the final set—for example, to
only the eight indicators from this set that were scored relevant
for all dimensions. The latter set would probably be more useful
also for feedback to individual prescribers, since the relevance
to the dimensions ‘‘patient health benefit’’ and ‘‘cost effective-
ness’’ was scored higher compared with our final set. Yet, we
believe that, provided their limitations are taken into account,
the indicators of the final set are valid as a signals
( = indicators) that call for more detailed analysis.
Benchmarking by comparisons between countries has proven
to be important stimulus to quality improvement. This applies
to antibiotic consumption as well.30 The set of indicators on
outpatient antibiotic use presented here could allow individual
countries to assess their position in relation to other countries,
and trigger actions to improve antimicrobial prescribing. It
could also allow identifying temporal trends and regional
differences and therefore trigger investigation and action at the
regional level. Finally, the set of indicators will be available to
inform the process of development, implementation and
evaluation of national and regional guidelines, and thus be
useful for policy makers and medical professionals. However,
defining benchmarks for this set of indicators on the basis of
currently available ESAC data requires taking into account
several contextual factors, such as local epidemiology of infectious
diseases and local guidelines. Consequently this needs to be
undertaken at a national level and might prove to be a difficult
exercise. After all, some of the variations revealed by routine data
may reflect real and important variations in actual healthcare
quality, that is, inappropriate antibiotic use,7 13–17 that merit
further investigation and action, but some apparent variation
may also arise because of other misleading factors such as
unadjusted casemix differences.1 Although measures of process
may be less susceptible to spurious variations than measures of
outcome, judgments about the quality of care should always be
made with caution when using routine comparative data.
Figure 2 Outpatient antibiotic use in 28
European countries in 2004. Consumption
of antibacterials for systemic use (ATC J01)
in ambulatory care is expressed in DDD per
thousand inhabitants per day; for Greece
and Iceland total data were used, for Poland
2002 data, and for Estonia and Italy 2003
data were used. DDD, defined daily dose;
ESAC, European Surveillance of
Antimicrobial Consumption.
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In conclusion, our work could be considered as a solid, but
first step in the development of a set of valid quality indicators
for outpatient antibiotic use in Europe. The challenge is to
create indicators that are equally relevant across countries in
Europe. In addition, more work is needed for indicators to be
useful for individual prescribers. Until then even without
correction for casemix, the patterns of resistance and other
contextual factors, the reported set of ESAC-based indicator
values provides valuable information about the appropriateness
of antibiotic use in Europe in the context of the alarming levels
of antimicrobial resistance.
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